Search research articles
Contact Us
Filters
Showing results (81-90 of 98) with videos related to
Page
of 10
Sort By:
ESMO Open
|
November 10, 2022
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
M Schmidt, K Lübbe, T Decker, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 31, 2006
Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors
Bryan Sorensen, Martin Winn, Jeff Rohde, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
Journal of Medicinal Chemistry
|
August 5, 2005
Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators
J T Link, Bryan Sorensen, Jyoti Patel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P A Fasching, T Link, J Hauke, et al.
ESMO Open
|
April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P Meyer-Wilmes, J Huober, M Untch, et al.
Journal of Medicinal Chemistry
|
August 6, 2004
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes
Thomas W von Geldern, Noah Tu, Philip R Kym, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 18, 2006
Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation
Jyoti R Patel, Qi Shuai, Jurgen Dinges, et al.
Iscience
|
January 19, 2026
Mitigating increasing wildfire risk through fuel break innovations
Nicholas T Link, Jill F Johnstone, Xanthe J Walker, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes
Peer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 98) with videos related to
Sort By:
Page
of 10
ESMO Open
|
November 10, 2022
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
M Schmidt, K Lübbe, T Decker, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 31, 2006
Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors
Bryan Sorensen, Martin Winn, Jeff Rohde, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
Journal of Medicinal Chemistry
|
August 5, 2005
Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators
J T Link, Bryan Sorensen, Jyoti Patel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P A Fasching, T Link, J Hauke, et al.
ESMO Open
|
April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P Meyer-Wilmes, J Huober, M Untch, et al.
Journal of Medicinal Chemistry
|
August 6, 2004
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes
Thomas W von Geldern, Noah Tu, Philip R Kym, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 18, 2006
Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation
Jyoti R Patel, Qi Shuai, Jurgen Dinges, et al.
Iscience
|
January 19, 2026
Mitigating increasing wildfire risk through fuel break innovations
Nicholas T Link, Jill F Johnstone, Xanthe J Walker, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes
Peer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Page
of 10